Journal ArticleDOI
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma.
Saurabh Zanwar,Shaji Kumar +1 more
TLDR
In this paper, the authors discuss the currently existing data on prognostic and predictive biomarkers in multiple myeloma and speculate the role of treatment stratification based on the genetic features of the disease.Abstract:
Multiple myeloma (MM) is a clonal plasma cell malignancy with a heterogeneous disease course. Insights into the genetics of the disease have identified certain high-risk cytogenetic features that are associated with adverse outcomes. While the advances in therapy have translated into dramatic improvements in the outcome of patients with MM, those with high-risk genetic features continue to perform poorly. This has resulted in a need for clinical trials focusing on the high-risk subgroup of MM as they search for additional biomarkers and therapeutic targets continue. In this review, we discuss the currently existing data on prognostic and predictive biomarkers in MM and speculate the role of treatment stratification based on the genetic features of the disease.read more
Citations
More filters
Posted ContentDOI
Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients
TL;DR: In this article , the authors evaluated the effect of the Barthel index (BI) on the prognosis of newly diagnosed multiple myeloma patients and found that low BI was associated with shorter median overall survival and progression-free survival.
Journal ArticleDOI
Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients
Chuanying Geng,Guangzhong Yang,Huixing Zhou,Huijuan Wang,Yanchen Li,Yun Leng,Zhiyao Zhang,Yang Jiang,Wenming Chen +8 more
TL;DR: In this article , the authors evaluated the effect of the Barthel index (BI) on the survival of newly diagnosed multiple myeloma (MM) patients and found that the low BI was a poor prognostic factor for patients with newly diagnosed MM.
References
More filters
Journal ArticleDOI
Fibroblast growth factor signalling: from development to cancer
Nicholas C. Turner,Richard Grose +1 more
TL;DR: There is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumour types, and clinical reagents that specifically target the FGFs or FGF receptors are being developed.
Journal ArticleDOI
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Maria-Victoria Mateos,Kenneth C. Anderson,Dixie Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Paul G. Richardson +20 more
TL;DR: Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.
Journal ArticleDOI
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
TL;DR: The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Journal ArticleDOI
Initial genome sequencing and analysis of multiple myeloma
Michael A Chapman,Michael S. Lawrence,Jonathan J Keats,Kristian Cibulskis,Carrie Sougnez,Anna C. Schinzel,Christina L. Harview,Jean Philippe Brunet,Gregory J. Ahmann,Mazhar Adli,Mazhar Adli,Kenneth C. Anderson,Kristin G. Ardlie,Daniel Auclair,Angela Baker,P. Leif Bergsagel,Bradley E. Bernstein,Bradley E. Bernstein,Bradley E. Bernstein,Yotam Drier,Yotam Drier,Rafael Fonseca,Stacey Gabriel,Craig C. Hofmeister,Sundar Jagannath,Andrzej Jakubowiak,Amrita Krishnan,Joan Levy,Ted Liefeld,Sagar Lonial,Scott Mahan,Bunmi Mfuko,Stefano Monti,Louise M. Perkins,Robb Onofrio,Trevor J. Pugh,S. Vincent Rajkumar,Alex H. Ramos,David S. Siegel,Andrey Sivachenko,A. Keith Stewart,Suzanne Trudel,Ravi Vij,Douglas Voet,Wendy Winckler,Todd Zimmerman,John D. Carpten,Jeff Trent,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway,Matthew Meyerson,Matthew Meyerson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Gad Getz,Todd R. Golub +58 more
TL;DR: The massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs indicates that cancer genome sequencing of large collections of samples will yield new insights into cancer not anticipated by existing knowledge.
Journal ArticleDOI
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
Shaji Kumar,Angela Dispenzieri,Martha Q. Lacy,Morie A. Gertz,Francis K. Buadi,Shivlal Pandey,Prashant Kapoor,David Dingli,Suzanne R. Hayman,Nelson Leung,John A. Lust,Arleigh McCurdy,Stephen J. Russell,Steven R. Zeldenrust,Robert A. Kyle,S V Rajkumar +15 more
TL;DR: It is demonstrated that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably, highlighting the impact of initial therapy with novel agents.
Related Papers (5)
Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice
Ola Landgren,Gareth J. Morgan +1 more